Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-210M | $-223M | $-190M | -80.5% | - | -13.8% |
| 2024 | $0M | $-247M | $-259M | $-216M | -55.9% | - | 5.4% |
| 2023 | $0M | $-237M | $-246M | $-211M | -49.9% | - | 10.7% |
| 2022 | $0M | $-214M | $-222M | $-187M | -45.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 223.84 | 259.66 | 273.20 | 228.52 |
| Research And Development | - | 165.57 | 186.34 | 171.24 | 142.01 |
| Selling General And Administration | - | 58.77 | 73.32 | 101.96 | 86.50 |
| Total Expenses | - | 223.84 | 259.66 | 273.20 | 228.52 |
| Operating Income | - | -223.84 | -259.66 | -273.20 | -228.52 |
| Total Operating Income As Reported | - | -224.34 | -259.66 | -273.20 | -231.75 |
| EBITDA | - | -213.69 | -236.62 | -247.48 | -210.21 |
| Normalized EBITDA | - | -213.69 | -236.62 | -247.48 | -206.98 |
| EBIT | - | -219.95 | -243.72 | -256.86 | -221.23 |
| Interest Income | - | 3.89 | 15.94 | 16.34 | 10.52 |
| Interest Expense | - | 1.91 | 1.88 | 1.89 | 1.89 |
| Net Interest Income | - | 1.98 | 14.06 | 14.46 | 8.62 |
| Other Income Expense | - | - | - | - | -3.23 |
| Interest Income Non Operating | - | 3.89 | 15.94 | 16.34 | 10.52 |
| Interest Expense Non Operating | - | 1.91 | 1.88 | 1.89 | 1.89 |
| Net Non Operating Interest Income Expense | - | 1.98 | 14.06 | 14.46 | 8.62 |
| Pretax Income | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Net Income From Continuing And Discontinued Operation | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Net Income From Continuing Operation Net Minority Interest | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Net Income | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Net Income Common Stockholders | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Net Income Including Noncontrolling Interests | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Normalized Income | - | -221.86 | -245.60 | -258.75 | -219.89 |
| Diluted NI Availto Com Stockholders | - | -221.86 | -245.60 | -258.75 | -223.12 |
| Basic Average Shares | - | 68.15 | 84.01 | 94.81 | 111.12 |
| Diluted Average Shares | - | 68.15 | 84.01 | 94.81 | 111.12 |
| Reconciled Depreciation | - | 6.27 | 7.10 | 9.38 | 11.02 |
| Total Unusual Items | - | - | - | 0 | -3.23 |
| Total Unusual Items Excluding Goodwill | - | - | - | 0 | -3.23 |
| Special Income Charges | - | - | - | 0 | -3.23 |
| Restructuring And Mergern Acquisition | - | - | - | 0 | 3.23 |
| General And Administrative Expense | - | 58.77 | 73.32 | 101.96 | 86.50 |
| Other Gand A | - | 58.77 | 73.32 | 101.96 | 86.50 |
| Other Operating Expenses | -1 | -0.50 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc.this co. | RCKT | $319M | -1.43 | 1.15 | -80.5% | -1.27 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Organogenesis Holdings Inc. | ORGO |
| - |
| - |
| - |
| - |
| - |
| $319M |
| 8.62 |
| 1.06 |
| 12.3% |
| 3.71 |
| Fennec Pharmaceuticals Inc. | FENC | $318M | -32.67 | 8.97 | -27.5% | -37.76 |
| SIGA Technologies, Inc. | SIGA | $318M | 13.65 | 1.60 | 11.7% | 6.73 |
| DiaMedica Therapeutics Inc. | DMAC | $315M | - | 5.61 | -58.4% | - |
| Electromed, Inc. | ELMD | $304M | 40.34 | 7.04 | 17.4% | 26.66 |
| Peer Median | - | 8.62 | 3.96 | 12.0% | 3.54 | |
Historically, Feb has averaged the highest return (+5.9%); Mar the lowest (-17.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.9%Neutral MonthJan 2026: -0.85% | +44.0%Positive MonthFeb 2026: +43.97% | -28.5%Negative MonthMar 2026: -28.54% | -2.8%Negative MonthApr 2026: -2.79% | -11.8%Negative MonthMay 2026: -11.78% | +11.4%Positive MonthJun 2026: +11.40% | -9.1%Negative MonthJul 2026: -9.06% | +17.4%*Positive MonthAug 2026: +17.36% | — | — | — | — |
| 2025 | -14.6%Negative MonthJan 2025: -14.56% | -12.0%Negative MonthFeb 2025: -12.01% | -29.4%Negative MonthMar 2025: -29.42% | +14.4%Positive MonthApr 2025: +14.39% | -67.1%Negative MonthMay 2025: -67.10% | -2.4%Negative MonthJun 2025: -2.39% | +24.5%Positive MonthJul 2025: +24.49% | +7.5%Positive MonthAug 2025: +7.54% | -0.6%Neutral MonthSep 2025: -0.61% | +15.6%Positive MonthOct 2025: +15.64% | -9.3%Negative MonthNov 2025: -9.28% | +2.6%Positive MonthDec 2025: +2.63% |
| 2024 | -4.1%Negative MonthJan 2024: -4.14% | +2.0%Neutral MonthFeb 2024: +1.98% | -8.1%Negative MonthMar 2024: -8.05% | -20.1%Negative MonthApr 2024: -20.12% | -0.9%Neutral MonthMay 2024: -0.93% | +1.0%Neutral MonthJun 2024: +0.98% | +12.4%Positive MonthJul 2024: +12.40% | -22.1%Negative MonthAug 2024: -22.11% | -2.0%Negative MonthSep 2024: -2.02% | -9.9%Negative MonthOct 2024: -9.85% | -13.6%Negative MonthNov 2024: -13.57% | -12.6%Negative MonthDec 2024: -12.65% |
| 2023 | +11.0%Positive MonthJan 2023: +11.04% | -11.6%Negative MonthFeb 2023: -11.60% | -10.8%Negative MonthMar 2023: -10.83% | +4.6%Positive MonthApr 2023: +4.61% | +16.8%Positive MonthMay 2023: +16.80% | -5.1%Negative MonthJun 2023: -5.06% | -9.2%Negative MonthJul 2023: -9.16% | -13.3%Negative MonthAug 2023: -13.30% | +30.9%Positive MonthSep 2023: +30.93% | -11.7%Negative MonthOct 2023: -11.66% | +28.9%Positive MonthNov 2023: +28.90% | +28.5%Positive MonthDec 2023: +28.46% |
| 2022 | -23.8%Negative MonthJan 2022: -23.77% | +7.0%Positive MonthFeb 2022: +7.03% | -10.9%Negative MonthMar 2022: -10.95% | -35.2%Negative MonthApr 2022: -35.18% | +15.3%Positive MonthMay 2022: +15.27% | +16.1%Positive MonthJun 2022: +16.12% | +5.4%Positive MonthJul 2022: +5.38% | +6.3%Positive MonthAug 2022: +6.28% | +3.6%Positive MonthSep 2022: +3.57% | +16.9%Positive MonthOct 2022: +16.92% | +1.2%Neutral MonthNov 2022: +1.18% | +3.7%Positive MonthDec 2022: +3.65% |
| 2021 | — | — | — | — | -7.3%Negative MonthMay 2021: -7.29% | +4.2%Positive MonthJun 2021: +4.21% | -19.1%Negative MonthJul 2021: -19.12% | -4.5%Negative MonthAug 2021: -4.49% | -12.6%Negative MonthSep 2021: -12.63% | -0.6%Neutral MonthOct 2021: -0.60% | -17.8%Negative MonthNov 2021: -17.77% | -10.6%Negative MonthDec 2021: -10.64% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
